MedTrace Logo

A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

NCT05995249 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2024-02-06

No results posted yet for this study

Summary

The main aim of this study is to find out how the body of a healthy adult processes TAK-279 (pharmacokinetics) when substances that either hinder or help the human metabolism such as erythromycin, phenytoin and efavirenz are given along with TAK-279. Other aim is to learn about side effects and how well it is tolerated when TAK-279 is given alone and together with substances that impact human metabolism.

The participants will need to stay at the clinic for up to 26 days.

Conditions

  • Healthy Volunteers

Interventions

DRUG

TAK-279

TAK-279 capsules

DRUG

Erythromycin

Erythromycin tablets

DRUG

Phenytoin

Phenytoin capsules

DRUG

Efavirenz

Efavirenz tablets

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-11
Primary Completion
2023-12-18
Completion
2023-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05995249 on ClinicalTrials.gov